Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To determine the efficacies of entecavir (ETV) in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients and in those with prior lamivudine (LAM) use who did not develop resistance. Methods: We retrospectively enrolled 337 patients with CHB who were treated with ETV (0.5 mg daily) for at least 30 months. The study included 270 (80.1%) NA-naïve patients and 67 (19.9%) LAM-use patients. Ten of the LAM-use patients were refractory to LAM therapy without developing resistance. Results: Genotypic resistance to ETV developed more frequently in the LAM-use group (13.1%) than in the NA-naïve group (2.6%) at 60 months (P=0.009). In subgroup analysis, after excluding the 10 patients who were refractory to LAM therapy, the cumulative probability of ETV resistance did not differ significantly between the two groups (P=0.149). Prior LAM refractoriness and a higher hepatitis B virus DNA level at month 12 were independent predictive factors for the development of ETV resistance. Conclusions: ETV resistance developed more frequently in LAM-use patients with CHB. However, prior LAM use without refractoriness did not affect the development of ETV resistance. The serum hepatitis B virus DNA level at month 12 was a major predictor for the development of ETV resistance. (Clin Mol Hepatol 2015;21:131-140)
Abstract
Background/Aims: To determine the efficacies of entecavir (ETV) in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients and in those with prior lamivudine (LAM) use who did not develop resistance. Methods: We retrospectively enrolled 337 patients with CHB who were treated with ETV (0.5 mg daily) for at least 30 months. The study included 270 (80.1%) NA-naïve patients and 67 (19.9%) LAM-use patients. Ten of the LAM-use patients were refractory to LAM therapy without developing resistance. Results: Genotypic resistance to ETV developed more frequently in the LAM-use group (13.1%) than in the NA-naïve group (2.6%) at 60 months (P=0.009). In subgroup analysis, after excluding the 10 patients who were refractory to LAM therapy, the cumulative probability of ETV resistance did not differ significantly between the two groups (P=0.149). Prior LAM refractoriness and a higher hepatitis B virus DNA level at month 12 were independent predictive factors for the development of ETV resistance. Conclusions: ETV resistance developed more frequently in LAM-use patients with CHB. However, prior LAM use without refractoriness did not affect the development of ETV resistance. The serum hepatitis B virus DNA level at month 12 was a major predictor for the development of ETV resistance. (Clin Mol Hepatol 2015;21:131-140)
참고문헌 (25)
- Shepard CW, "Hepatitis B virus infection : epidemiology and vaccination", Epidemiol Rev, 28, pp.112~125 (2006)
- Fattovich G, "Natural history of chronic hepatitis B : special emphasis on disease progression and prognostic factors", J Hepatol, 48, pp.335~352 (2008)
- European Association For The Study Of The Liver, "EASL clinical practice guidelines : Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Hadziyannis SJ, "Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 32, pp.847~851 (2000)
- Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates : results after 3years of therapy", Hepatology, 33, pp.1527~1532 (2001)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Fung J, "Nucleoside", nucleotide analogues in the treatment of chronic hepatitis B, 2011, pp.66, 2715~2725
- Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine", Antimicrob Agents Chemother, 48, pp.3498~3507 (2004)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Reijnders JG, "Antiviral effect of entecavir in chronic hepatitis B : influence of prior exposure to nucleos(t)ide analogues", J Hepatol, 52, pp.493~500 (2010)
- Ide T, "Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy", Hepatol Int, 4, pp.594~600 (2010)
- Lee JH, "Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance", Antimicrob Agents Chemother, 58, pp.1730~1737 (2014)
- Ono A, "Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients", J Hepatol, 57, pp.508~514 (2012)
- Suzuki F, "Efficacy of switching to entecavir monotherapy in Japanese lamivudinepretreated patients", J Gastroenterol Hepatol, 25, pp.892~898 (2010)
- Liaw YF, "2-Year GLOBE trial results : telbivudine Is superior to lamivudine in patients with chronic hepatitis B", Gastroenterology, 136, pp.486~495 (2009)
- Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
- Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34, pp.785~791 (2001)
- Zeuzem S, "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B", J Hepatol, 51, pp.11~20 (2009)
- 권대훈, "Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response", Gut and Liver, 7(6), pp.712~718 (2013), 거트앤리버 발행위원회
- Bang SJ, "Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B", Dig Liver Dis, 45, pp.600~605 (2013)
- Baran B, "Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside", nucleotide analogue-naive patients with chronic hepatitis B, 2013, pp.57, 1790~1796
- Corsa AC, "No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B", Clin Gastroenterol Hepatol, 12, pp.2106~2112 (2014)
- Fung S, "Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 146, pp.980~988 (2014)